Biotech News
Related news
EXELExelixis2026-08-31 18:30 EST
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
LYELLyell Immunopharma2026-09-10 20:05 EST
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
RVMDRevolution Medicines2026-09-02 21:50 EST
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
IDYAIDEAYA Biosciences2026-09-09 10:00 EST
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
BMEABiomea Fusion2026-08-24 11:00 EST
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
ARGXArgenx2026-08-17 05:00 EST
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
NRIXNurix Therapeutics2026-08-04 05:00 EST
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
INBXInhibrx2026-09-04 20:00 EST
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Exelixis
Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...
Recent company news
EXELExelixis2026-09-01 20:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
EXELExelixis2026-08-31 18:30 EST
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
EXELExelixis2026-08-05 20:05 EST
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
EXELExelixis2026-07-22 20:30 EST
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
EXELExelixis2026-06-22 12:00 EST
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Stock data
- Close
- 58.36 USD
- Market cap
- 12.2B USD
- Exchange
- NASDAQ
- Sector
- Small Molecule Drugs
- Location
- United States